Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Detailed price information for Exlservice Holdings (EXLS-Q) from The Globe and Mail including charting and trades.

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

William Blair analyst Matt Larew maintained a Hold rating on Amedisys today. The company’s shares closed yesterday at $97.52. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...

Mastercard eased concerns about a potential slowdown in consumer spending after beating Wall Street estimates for ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...